Table 1.
Demographic characteristics, clinical symptoms and SARS-CoV-2 lineage data from a cohort of outpatient participants in Los Angeles County and Riverside County, California, May 27, 2021 to September 9, 2021 (n = 503).
| Variable | Mean/number | Standard deviation or percent |
|---|---|---|
| Age, years | 40.9 | 12.6 |
| Gender, female | 238 | 47.3% |
| Days to collection | 2.8 | 0.7 |
| Ethnicity | ||
| Not disclosed | 25 | 5.0% |
| Black or African American | 1 | 0.2% |
| Hispanic or Spanish origin | 221 | 43.9% |
| Not Hispanic or Spanish origin | 208 | 41.4% |
| Prefer not to share | 48 | 9.5% |
| Vaccinated | ||
| No | 182 | 36.2% |
| Yes | 320 | 63.6% |
| Declined to disclose | 1 | 0.2% |
| Vaccine manufacturer | ||
| J&J | 56 | 16.6% |
| Moderna | 98 | 29.1% |
| Pfizer | 179 | 53.1% |
| Pfizer and AstraZeneca | 1 | 0.3% |
| Sinopharm | 3 | 0.9% |
| Symptoms | ||
| Congestion or runny nose | 375 | 75.6% |
| Cough | 368 | 74.2% |
| Fatigue | 343 | 69.2% |
| Headache | 301 | 60.7% |
| Muscle or body aches | 290 | 58.5% |
| New loss of taste or smell | 289 | 58.3% |
| Fever or chills | 220 | 44.4% |
| Sore throat | 216 | 43.5% |
| Shortness of breath | 125 | 25.2% |
| Diarrhea | 105 | 21.2% |
| Nausea or vomiting | 80 | 16.1% |
| Bleeding | 1 | 0.2% |
| Eye redness or dry mouth | 1 | 0.2% |
| Stomach pain | 1 | 0.2% |